Abstract
We describe the toxicity and efficacy of DLI given to 81 patients (median 50 years) after RIC transplants performed by 16 UK centres. The diseases treated were NHL (29), CML (12), myeloma (11) , AML (10) and CLL (9) . 88% received stem cells from sibling donors. The patients received 130 infusions (median 1, range 1-4). Indications for DLI were unsatisfactory response/disease progression (51), mixed chimerism (18), 10 pre-emptive and two other. Graft hypoplasia was uncommon (11%). Grade II-IV GVHD occurred in 23/81 patients (28%) and limited and extensive chronic GVHD in 5/69 and 18/69 evaluable patients (total incidence 33%). Conversion from mixed to full donor chimerism occurred in 19/55 evaluable patients (35%) at a median of 48 days after the DLI; partial responses occurred in 6 patients (total response rate 45%). Eighteen of 51 (35%) patients with measurable disease post-SCT had a CR (2 molecular), and 5 a PR (total response rate 45%). 11/17 evaluable complete responders had full donor chimerism. 8/13 patients with follicular NHL had complete responses and 4/12 patients with CML. Clinical and chimeric responses correlated strongly with acute and chronic GVHD. Forty seven patients (58%) survive at a median of 508 days post-SCT (range 155-1171 days) with a median Karnofsky score of 90. Thirty four patients (42%) died at a median of 211 days post transplant with the major causes being progressive disease (26%) and GVHD (9%). Further, systematic studies are required to determine the efficacy and optimum use of DLI for patients with each disease treated with non-myeloablative SCT.
Introduction
Reduced intensity conditioning (RIC) allografts, using non-myeloablative conditioning, have been undertaken recently for a variety of haematological [1] [2] [3] and solid tumours 4 . Their aim is to reduce short-term transplant related morbidity and mortality with the intention of providing a platform for a subsequent graft versus malignancy (GVM) effect by early withdrawal of post-transplant immunosuppression or donor lymphocyte infusions (DLI). There are a number of indications for DLI after RIC allografts. Firstly RIC transplants often result in mixed donor and recipient chimerism (MC). In published data from the three most commonly used regimens in the UK, mixed chimerism occurred in 42%, 36% and 73% of cases analyzed, respectively 1, [5] [6] . Sometimes, as the Seattle group 3 has shown, a shift to full donor chimerism spontaneously results, but this is not invariably the case. Although graft versus host disease (GVHD) can occur in the setting of mixed chimerism 7 overall there is less chance of a durable GVM effect and there may be a higher chance of graft rejection. Thus conversion to full donor chimerism following administration of DLI is likely to be beneficial in terms of both disease control and survival. A second important indication for DLI is disease progression or the failure of the transplant to achieve a complete remission. This may be more common with less intensive conditioning. Donor lymphocyte infusions when given for chronic phase chronic myeloid leukemia, that has relapsed after conventional allogeneic SCT, result in a high incidence of durable cytogenetic and molecular remissions [8] [9] [10] . Their efficacy for other haematological diseases is much less well documented [11] [12] and it is only multicentre collaborative studies that have collected sufficient patients in each disease category that enables us to assess the likelihood of their efficacy in diseases such as AML [11] [12] or multiple myeloma [13] [14] . Thirdly, DLI are being increasingly given empirically in the post-transplant setting, as a pre-emptive strike against disease relapse or on the assumption that they may eliminate undetectable minimal residual disease. RIC allografts confront physicians with a number of novel clinical situations in which decisions need to be made. When faced with the need to prescribe DLI we found that there was virtually no published information defining optimal cell dose and timing of these infusions. As a result, it is not possible to advise individual patients accurately about the chance of success. Similarly, data on the probability of severe toxicities such as graft hypoplasia and severe acute and chronic GVHD is scarce and may only become clear with large scale studies. In order to address these issues we report here the results of a national survey of 81 patients transplanted at 16 centres who received DLI following RIC allogeneic transplantation.
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Methods

Patients
Twenty eight adult allogeneic transplant centres in the United Kingdom were invited to participate in a study concerning the administration of DLI after RIC allografts. Five centres had performed no RIC-allografts or had not given DLI after these procedures. Sixteen of the remaining 23 centres (70%) provided data on 81 patients. These data represent all patients given DLI who received RIC allografts at these centres. The clinical characteristics of the patients are shown in table 1. The major diseases treated were non-Hodgkin's lymphoma (29), CML (12), myeloma (11), AML (10) and CLL (9) . Remission status was favourable in 17, intermediate in 45 and unfavourable in 19. The majority of patients received one of two transplant protocols: 37/81 patients had received fludarabine, melphalan and Campath 1H 1 and 21 received carmustine, etoposide, ara-C, melphalan and Campath 1H 5 . Seventy one received stem cells from sibling donors (88%) and 10 from unrelated donors (UD-only 1 mismatched). Fourteen (17%) experienced GVHD prior to the administration of DLI. We also collected basic demographic data from patients at the same centres who received RIC allografts but did not require DLI. These data were from 264 patients transplanted at 15 of 16 of the same centres reporting the 81 study patients (table 2) . In comparison to the group who received DLI their median age was slightly lower (47.5 vs 50 years, p=0.084, Mann-Whitney U-test), they received stem cells more from donors other than matched siblings (p=0.003, continuity corrected Chi-squared test) and there were more patients with AML (28% vs 12%) and fewer with CML (7% vs 15%). The reasons for these patients not receiving DLI are presented in table 2. The most common reasons were that the patient was in CR or that the patient's overall condition was poor.
Non-myeloablative conditioning protocols and GVHD prophylaxis Four major protocols were used: Regimen A: The most frequently used protocol involves fludarabine (30 mg/m 2 ) day -7 to -3, Campath -1H (10mg twice daily) from day -7 to -3 and melphalan 140 mg/m 2 on day -2 followed by stem cell infusion on day 0 1 . Cyclosporin was the sole immunosuppressive agent given post transplant. Regimen B: The BEAM-Campath regimen: carmustine (300mg/m 2 ) day -6, cytosine arabinoside (200 mg/m 2 twice daily) days -5 to -2, etoposide (200 mg/m 2 ) days -5 to -2 and melphalan (140 mg/m 2 ) day -1. Campath -1G (10 mg/day) or Campath -1H (20 mg/day) were given continuously from day -5 to -1 inclusive. Some patients on this protocol received fludarabine (30 mg/m 2 ) days -9 to -7. GVHD prophylaxis was with cyclosporin and 3 doses of methotrexate (10 mg/m 2 ) on days 1, 3 and 6 5 . Regimen C: busulfan 8 mg/kg given in 2 days, fludarabine 30 mg/m 2 for 5 days and a Miltenyi CD34 selection of the graft with planned DLI at 180, 270 and 360 days 6 . Cyclosporin is given post-transplant. Regimen D: Fludarabine 30 mg/m 2 for 5 days and cyclophosphamide 1g IV for 2 days. The graft was given unmanipulated.
Techniques for assessing chimerism We asked reporting centres to categorize their method of assessing chimerism. Multilineage chimerism was performed using DNA extracted from granulocytes and T-cells with the identification of an informative microsatellite marker (n=18). Unseparated chimerism was performed on whole blood with no separation of T-cells and granulocytes (n=53). Fluorescent in situ hybridisation (FISH) using X and Y specific probes was the method of assessing chimerism in some donor-recipient sex mismatched transplants (n=5). Five patients who were given DLI did not have chimerism studies performed. Where known, peripheral blood (n=27), marrow (n=17) or both (n=29) were analysed in the specimen prior to the first DLI.
Definitions A complete haematological response means no detectable disease at the morphological, biochemical, clinical and radiological level. Some patients with CML and follicular NHL who had complete clinical responses were assessed for molecular remission. A partial response (PR) denotes a >50% reduction in measurable tumour, a >50% reduction in the serum paraprotein level in patients with myeloma or a response to <10% blasts in patients with acute leukaemia. Status at transplant was categorized as CR1, CR2, >CR3, PR, sensitive relapse, untested relapse, resistant relapse or primary refractory disease. Favourable remission status comprised CR1 and CR2; intermediate status consisted of PR, sensitive relapse and >CR3 while untested or resistant relapse and primary refractory disease were categorised as unfavourable. A complete chimeric response was used to denote conversion of mixed to full donor chimerism. A partial chimeric response was used to describe a >20% increase in the number of donor cells, whatever method was used. Graft hypoplasia was defined as the development of a neutrophil count of <1 x 10 9 /l and/or a platelet count of <20 x 10 9 /l in the presence of a hypocellular marrow. Acute GVHD was graded according to the modified Glucksberg criteria 15 and chronic GVHD classified as none, limited and extensive. There were various indications for DLIs. The most common were for disease relapse or progression or persistent mixed chimerism. In many cases it was part of the RIC allograft protocol and was given even if there was no overt disease and full donor chimerism. In other cases the chance of relapse was considered high enough to give DLI pre-emptively.
Statistics
For the patients who received DLI the outcome measures considered were acute GVHD (any or >grade II), any chronic GVHD, complete clinical or chimeric responses, where these were evaluable. The proportions with adverse outcomes for various subgroups were compared using Chi-squared tests; for 2 x 2 tables a continuity correction was used or two-tailed Fisher's exact test where expected frequencies were small. Two tailed Mann-Whitney U-tests were employed to compare good and poor responders with respect to continuous variables such as age and maximum DLI dose. Kaplan Meier survival estimates were calculated from the last date of patient contact and the survival of subgroups of patients were compared using logrank tests. The Cox proportional hazards model was used to examine the effect of continuous variables on survival. Minimum follow up of survivors was five months from the date of the transplant.
Results
Donor lymphocyte infusions and indications
The patients received a total of 130 infusions (median 1, range 1-4). The indications for DLI were unsatisfactory response/disease progression (51), mixed chimerism (18) and 10 were pre-emptive and one each were given for autoimmune haemolytic anaemia 16 and progressive CMV retinitis (table 3) . Eight patients received DLI as part of the transplant protocol. Nine had specific antitumoural therapy prior to DLI. Seven of these nine patients had lymphoma, one had myeloma and one AML. Two patients received local radiotherapy alone and seven received chemotherapy. Of the 7 who were administered chemotherapy, 3 had additional rituximab, one had local radiotherapy and one had thalidomide. Ten patients were being administered immunosuppressive agents at the time of DLI. The reasons for this are as follows: 3 had ongoing or recent GVHD, one was given DLI for CMV retinitis and 1 received DLI to correct mixed chimerism. In 5 of 10 cases the reason is not known. The median times of the first, second and third DLI were 149 (range 61-1008 days), 210 (range 119-1029) and 303 (range 105-1111) days post SCT and the median CD3+ cell doses were 5 x 10 6 /kg (range 1x10 5 /kg to 1 x 10 8 /kg), 1 x 10 7 /kg (3 x 10 6 /kg to 1 x 10 8 /kg) and 5 x 10 7 /kg (10 7 /kg to 10 8 /kg) respectively. As the patients came from 16 different centres there was no consistent approach about the timing of DLI and the 'gaps' between DLI and the dose escalation schemes used were highly variable. Toxicity All patients were considered evaluable for graft hypoplasia and acute GVHD (table  4) . Graft hypoplasia was uncommon (9 of 81 patients=11%) and usually rapidly reversible. Five of 9 received hematopoietic growth factors but none required additional stem cells. Eight of nine patients with post DLI pancytopenia had mixed chimerism documented prior to the administration of DLI. Three of the nine patients with pancytopenia post-DLI had other possible contributing causes. Grade II-IV GVHD occurred in 27/81 patients (33%) and limited and extensive chronic GVHD in 5/69 and 18/69 evaluable patients respectively (total incidence of 33%). In total, 36 of 82 patients (44%) experienced either acute or chronic GVHD. The incidence of acute GVHD was not higher in unrelated donors (data not shown) although numbers were small. Seven patients (9%) died of DLI-related GVHD. An analysis of the possible relationship between GVHD and DLI dose in the 71 recipients of sibling allografts is shown in table 5. We were unable to demonstrate an association between acute, chronic or any GVHD and the maximum DLI dose delivered. We also assessed the toxicity of DLI given in the first 6 months after transplant as there is little published data concerning this. When the first DLI infusion was given <100 days post-SCT (n=19) the chances of acute, chronic and any GVHD were 37%, 28% and 53% respectively. For DLI given <180 days (n=47) the chances were 43%, 34% and 55% respectively. These figures are not statistically significantly different from patients who received DLI after day 180. More males developed chronic GVHD than females (41% vs 15%, p=0.075). Of the 14 patients who had GVHD prior to the first DLI, 5 developed acute GVHD and 3 chronic GVHD.
Hematological and chimeric responses Fifty one patients received DLI for measurable disease following their RIC allograft,. Of these, 18 (35%) patients had a complete remission of which 2 were molecular and 5 had a partial response. Thus the total clinical response rate was 45% while 13
patients remained in CR at the time of last patient contact. Details of the 18 complete responders are shown in table 6. The median follow-up of the 15 surviving complete responders is 700 days from SCT. The median time to a complete response was 132 days and the median duration of complete responses in surviving patients is 220 days. All surviving complete responders remain in CR at the time of analysis. Eleven of the 17 complete responders (65%) who had chimerism studies were shown to have full donor chimerism. 8/13 patients with overt follicular NHL post-SCT had complete responses and 2 additional patients who had pre-emptive DLI therapy remained in CR. Two patients with follicular lymphoma had very delayed complete responses to DLI (569 and 660 days respectively), were given single doses of DLI and received no other antitumoural therapy. 4/12 patients with CML had complete responses and 3 stayed in CR. Complete response rates were low in CLL (0/7, 1 PR), myeloma (0/10, 1 PR) and AML (1/7). The median DLI dose that resulted in a CR was 1 x 10 7 /kg (range 1 x 10 6 /kg to 3 x 10 7 /kg). Thirteen of the 18 complete responders experienced GVHD and 8 of the 13 both acute and chronic GVHD. A complete response was significantly associated with grade II-IV acute GVHD (p=0.005), any acute GVHD (p=0.010), chronic GVHD (p=0.014) and either acute or chronic GVHD (p=0.007). Of all the patients who developed either acute or chronic GVHD, 11 had no response and 4 were not evaluable for assessment of response as they were in CR at the time of receiving DLI. Of the 10 patients given DLI pre-emptively, 7 survive with 4 being in CR. GVHD prior to DLI was associated with a lower chance of a complete response (0% vs 33%, p=0.06). Of the 10 patients on immunosuppressive therapy at the time of DLI administration, 2 had complete responses and 4 remained in complete remission. Conversion to full donor chimerism occurred in 19/55 patients (35%) with documented at least partial recipient chimerism post RIC allograft at a median of 48 days after the DLI (range 24-690 days); partial (>20% increase in donor cells) responses were seen in an additional 6 patients. Thus the total chimeric response rate was 45%. A complete chimeric response was significantly associated with grade II-IV acute GVHD (p<0.001), any acute GVHD (p=0.006), chronic GVHD (p=0.007) and either acute or chronic GVHD (p<0.001).
Survival
Forty seven patients (58%) survive at a median follow-up of 508 days post-SCT (range 155-1171 days) with a median Karnofsky score of 90 but only 5 patients have a KS <80. The actuarial survival estimates at 1 and 2 years are 71% (59-80%, 95% CI) and 55% (42-66%, 95% CI) respectively (figure 1A). Twenty six patients (32%) survive in complete remission. Thirty two patients (40%) have died at a median of 211 days post transplant with the major causes being progressive disease (26%) and GVHD (9%). Disease status is significantly associated with survival (p=0.026) with the favourable and intermediate groups showing similar survival curves. This is shown graphically in figure 1B . The only other factor associated with survival is that patients who received therapy prior to DLI had a poorer survival (p=0.051). This, of course, may reflect a greater bulk of disease at the time of deciding to give DLI. There was no relationship between disease status and whether treatment was given prior to DLI so a multivariate analysis was not performed. 
Discussion
The last three years has seen an escalation of RIC transplants for a variety of diseases in the absence of evidence indicating durable efficacy. Three recent publications from London, Seattle and Houston, using very different transplant conditioning protocols, have helped to clarify short term toxicity and the degree of donor chimeric conversion that can be expected [1] [2] [3] . Considering the relatively poor prognosis of the patients who were transplanted, the reported one year survivals of 49-67% were encouraging and some documented molecular remissions have indicated that some patients may become long term survivors but, in 2002, it remains difficult to advise a candidate for a RIC allograft about the chance of being cured. RIC SCT has the advantage of being less toxic initially but the potential disadvantages of being less directly tumoricidal and having a higher chance of resulting in incomplete donor chimerism. The use of DLI has been central to the philosophy of many RIC SCT protocols. Some investigators have given DLI preemptively (as part of the protocol) while others have reserved them for disease progression or persistent mixed chimerism. A major practical difficulty for clinicians was that there was little data concerning the toxicity of early DLI and certainly no convincing published evidence that giving DLI is effective. Before drawing conclusions we should note that this multicentre national study has significant limitations. Although we have sampled >50% of the adult transplant centres in the UK we do not know if the data are representative of overall practice. Such limitations are common to much of the information concerning 'mini-allografts', namely heterogeneity of disease and remission status, short follow-up and widely varying transplant protocols. Nonetheless, this study has been performed to generate some large scale clinical data that may be sufficient to make some broadly based conclusions and recommendations and might enable us to make a subsequent systematic study of DLI. What can one conclude about toxicity? Grade II-IV acute GVHD was seen in approximately quarter of patients and severe (grade III-IV) acute GVHD in 15%. Chronic GVHD was seen in one third of patients. The incidence of both acute and chronic GVHD, while substantial, appears to be less than that reported after conventional allografts 12 but many patients in previous studies did not receive a program of incremental doses of DLI. DLI given in the first 6 months after transplant had a >50% chance of resulting in acute or chronic GVHD but we were unable to demonstrate an association between the maximum CD3+ cell dose given and the development of GVHD. However, this latter finding should be interpreted with caution because of the relatively small numbers of patients at each dose level. The only factor predictive of GVHD was male gender. In contrast to the London study reported at the recent American Society of Haematology meeting we did not find that DLI from unrelated donors were associated with more GVHD 17 . Procedural mortality was low (9%) 12 and the median KS of survivors is acceptable but over a third have chronic GVHD, most of it extensive. Irreversible graft hypoplasia did not appear to be a major problem in the dose ranges studied and no patient died of related neutropenic sepsis. It is harder to be definite about efficacy. DLI post RIC SCT are associated with a significant response rate but the median response duration of complete responders is only 7 months and relapse after DLI-induced remissions is well documented 8, 12 . The 81 patients comprise six main disease groups with small numbers in each group. The results of DLI are certainly very promising for follicular NHL and CML. It is only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From encouraging that 2 patients with follicular lymphoma are in molecular remission 5 but patients with this disease require prolonged follow-up to determine if they are cured. It is of interest that two patients with follicular NHL had very delayed responses to DLI. Thirteen additional patients have been in continuous CR since transplant (which also may be evidence of the efficacy of DLI) however, insufficient patients were given pre-emptive DLI to analyze the efficacy of this approach. In total, twenty six patients are currently candidates to become long term disease free survivors but additional patients in the cohort may remit with subsequent DLI. Nearly three quarters of complete responders experienced GVHD (most of them both acute and chronic) and this study, similar to previous studies 12 , indicated a substantial overlap between a GVM effect and GVHD. Subsequent studies should focus on whether it is possible to identify DLI doses that result in a GVM effect without severe GVHD. In addition, DLI may be of lesser importance after certain transplant protocols (such as the Seattle regimen 3 ): this requires further study. It is also of interest that a third of evaluable patients were converted from mixed to full donor chimerism. However, further studies are required to determine if it is necessary to give DLI to patients with persistent mixed chimerism or whether they should be reserved for patients with overt disease. Patient with persistent mixed chimerism can experience GVHD 7 (and therefore may benefit from a graft versus malignancy effect) but they may also be at risk of graft rejection although stable mixed chimerism is seen in some preclinical models 18 . In summary, RIC allografting has been piloted in a number of centers and a proportion of patients who would not be eligible for conventional intensity allografts may become long term disease free survivors. However, the published data describe a very heterogeneous group of patients and do not provide a sound evidence base for future investigations. It is important now to establish who will benefit most from these transplants and the optimal ways of performing them. The data in this report provide the information necessary to perform a systematic study of the role of DLI following RIC allografts. Although further follow-up is required to determine if the complete responders are cured the central premise that RIC allografts can provide a platform for subsequent effective cellular immunotherapy appears to have been confirmed. Nonetheless, many important questions need to be answered. Similar to the New York study in full intensity allografts 9 a phase I study that examines the relationship between CD3+ cell dose and toxicity should be performed. Age, source of stem cells and possibly other factors such as the RIC regimen may be variables to control for. Similar systematic studies need to be performed for each disease as the efficacy of DLI may depend on the disease being treated. In addition, the role of preemptive therapy in patients with diseases at high risk of relapse requires further evaluation. Some of these studies will require multicentre collaboration to generate sufficient numbers. 
